Direct oral anticoagulants (DoaCs) offer significant benefits for the treatment of nonvalvular atrial fibrillation and venous thromboembolism. these agents are simpler to use than others, as they do not require routine laboratory monitoring and dose adjustment. moreover, DoaCs have been shown to reduce severe bleedings, and especially intracranial bleedings, as compared to vitamin k antagonists. real-life clinical data confirmed these benefits that had previously been shown in randomized clinical trials.
Direct oral anticoagulants, atrial fibrillation, venous thromboembolism